Placebo News and Research

RSS

New natural supplement shows promise in preventing postpartum blues

A new study published in the Lancet discovery science journal eClinicalMedicine has confirmed that a novel natural supplement-;invented, researched, developed and commercialized at the Centre for Addiction and Mental Health (CAMH)-;prevents postpartum blues, and reduces symptoms of postpartum depression over the following six months after giving birth.

10 Apr 2024

Probiotics plus vitamin D supplements may improve cognitive function in individuals with schizophrenia

Previous studies have questioned whether gut microbe imbalances and vitamin D deficiency may be linked to schizophrenia.

10 Apr 2024

SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths

study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.

9 Apr 2024

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.

8 Apr 2024

Ninerafaxstat shows good tolerability and safety in nonobstructive HCM patients

The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with evidence of improvements in symptoms and exercise capacity among people with nonobstructive hypertrophic cardiomyopathy (HCM), according to results of a 12-week phase 2 trial presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

DEPOSITION trial evaluates the use of topical tranexamic acid during heart surgery

Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically rather than intravenously did not meet its primary endpoint of reducing seizures and was stopped early due to an increased risk of bleeding events, according to research presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes did not meet its primary endpoint, but a preplanned subgroup analysis found a statistically significant effect of treatment in patients who were not taking SGLT2 inhibitors or GLP-1 RAs, which are antidiabetic medications that also have benefits for the heart.

8 Apr 2024

Edetate disodium-based chelation ineffective for heart attack patients with diabetes

People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium-based chelation, a therapy that draws lead and other toxic metals linked to increased risk of heart disease and stroke out of the body, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.

8 Apr 2024

Novel cholesterol removal strategy shows potential benefits post-heart attack

The first trial of a novel strategy for removing cholesterol from patients' arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology's Annual Scientific Session. However, the findings suggest that the strategy may be beneficial with longer follow-up.

8 Apr 2024

Study: Empagliflozin shows mixed results in heart attack patients

Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Interatrial shunt may offer differential benefits based on heart failure type

Patients with heart failure who had a small shunt inserted between the heart's left and right atria did not see any significant benefits overall compared with those who received a placebo procedure after a median of 22 months follow-up, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.

7 Apr 2024

Study questions routine use of beta blockers after heart attack

Taking beta blockers after a heart attack did not significantly reduce the risk of death or a second heart attack among people with normal heart pumping ability, as indicated by an ejection fraction of 50% or higher, according to a study presented at the American College of Cardiology's Annual Scientific Session.

7 Apr 2024

Study shows promise of zilebesiran injection in reducing systolic blood pressure

A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure by between 4 to 12 mmHg on average at three months in patients whose blood pressure had remained uncontrolled despite compliance with their medication regimen, according to a study presented at the American College of Cardiology's Annual Scientific Session.

7 Apr 2024

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.

4 Apr 2024

Unlocking role of the cerebellum in reward-based learning

If you reward a monkey with some juice, it will learn which hand to move in response to a specific visual cue – but only if the cerebellum is functioning properly.

4 Apr 2024

New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.

3 Apr 2024

Placebo News and Research

New natural supplement shows promise in preventing postpartum blues

Probiotics plus vitamin D supplements may improve cognitive function in individuals with schizophrenia

SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

Ninerafaxstat shows good tolerability and safety in nonobstructive HCM patients

DEPOSITION trial evaluates the use of topical tranexamic acid during heart surgery

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

Edetate disodium-based chelation ineffective for heart attack patients with diabetes

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Novel cholesterol removal strategy shows potential benefits post-heart attack

Study: Empagliflozin shows mixed results in heart attack patients

Interatrial shunt may offer differential benefits based on heart failure type

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Study questions routine use of beta blockers after heart attack

Study shows promise of zilebesiran injection in reducing systolic blood pressure

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Unlocking role of the cerebellum in reward-based learning

New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News